BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38102337)

  • 1. Suppression of super-enhancer-driven TAL1 expression by KLF4 in T-cell acute lymphoblastic leukemia.
    Noura M; Matsuo H; Yasuda T; Tsuzuki S; Kiyoi H; Hayakawa F
    Oncogene; 2024 Feb; 43(6):447-456. PubMed ID: 38102337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant TAL1 activation is mediated by an interchromosomal interaction in human T-cell acute lymphoblastic leukemia.
    Patel B; Kang Y; Cui K; Litt M; Riberio MS; Deng C; Salz T; Casada S; Fu X; Qiu Y; Zhao K; Huang S
    Leukemia; 2014 Feb; 28(2):349-61. PubMed ID: 23698277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TAL1 activation in T-cell acute lymphoblastic leukemia: a novel oncogenic 3' neo-enhancer.
    Smith C; Goyal A; Weichenhan D; Allemand E; Mayakonda A; Toprak U; Riedel A; Balducci E; Manojkumar M; Pejkovska A; Mücke O; Sollier E; Bakr A; Breuer K; Lutsik P; Hermine O; Spicuglia S; Asnafi V; Plass C; Touzart A
    Haematologica; 2023 May; 108(5):1259-1271. PubMed ID: 36632736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NKX3.1 is a direct TAL1 target gene that mediates proliferation of TAL1-expressing human T cell acute lymphoblastic leukemia.
    Kusy S; Gerby B; Goardon N; Gault N; Ferri F; Gérard D; Armstrong F; Ballerini P; Cayuela JM; Baruchel A; Pflumio F; Roméo PH
    J Exp Med; 2010 Sep; 207(10):2141-56. PubMed ID: 20855495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isoforms of the TAL1 transcription factor have different roles in hematopoiesis and cell growth.
    Sharma A; Mistriel-Zerbib S; Najar RA; Engal E; Bentata M; Taqatqa N; Dahan S; Cohen K; Jaffe-Herman S; Geminder O; Baker M; Nevo Y; Plaschkes I; Kay G; Drier Y; Berger M; Salton M
    PLoS Biol; 2023 Jun; 21(6):e3002175. PubMed ID: 37379322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Harnessing the MYB-dependent TAL1 5'super-enhancer for targeted therapy in T-ALL.
    Smith C; Touzart A; Simonin M; Tran-Quang C; Hypolite G; Latiri M; Andrieu GP; Balducci E; Dourthe MÉ; Goyal A; Huguet F; Petit A; Ifrah N; Baruchel A; Dombret H; Macintyre E; Plass C; Ghysdael J; Boissel N; Asnafi V
    Mol Cancer; 2023 Jan; 22(1):12. PubMed ID: 36650499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia.
    Mansour MR; Sanda T; Lawton LN; Li X; Kreslavsky T; Novina CD; Brand M; Gutierrez A; Kelliher MA; Jamieson CH; von Boehmer H; Young RA; Look AT
    J Exp Med; 2013 Jul; 210(8):1545-57. PubMed ID: 23857984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element.
    Mansour MR; Abraham BJ; Anders L; Berezovskaya A; Gutierrez A; Durbin AD; Etchin J; Lawton L; Sallan SE; Silverman LB; Loh ML; Hunger SP; Sanda T; Young RA; Look AT
    Science; 2014 Dec; 346(6215):1373-7. PubMed ID: 25394790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting dual oncogenic machineries driven by TAL1 and PI3K-AKT pathways in T-cell acute lymphoblastic leukemia.
    Lim FQ; Chan AS; Yokomori R; Huang XZ; Theardy MS; Yeoh AEJ; Tan SH; Sanda T
    Haematologica; 2023 Feb; 108(2):367-381. PubMed ID: 36073513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RUNX1 is required for oncogenic
    Choi A; Illendula A; Pulikkan JA; Roderick JE; Tesell J; Yu J; Hermance N; Zhu LJ; Castilla LH; Bushweller JH; Kelliher MA
    Blood; 2017 Oct; 130(15):1722-1733. PubMed ID: 28790107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia.
    Sanda T; Lawton LN; Barrasa MI; Fan ZP; Kohlhammer H; Gutierrez A; Ma W; Tatarek J; Ahn Y; Kelliher MA; Jamieson CH; Staudt LM; Young RA; Look AT
    Cancer Cell; 2012 Aug; 22(2):209-21. PubMed ID: 22897851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional regulatory networks downstream of TAL1/SCL in T-cell acute lymphoblastic leukemia.
    Palomero T; Odom DT; O'Neil J; Ferrando AA; Margolin A; Neuberg DS; Winter SS; Larson RS; Li W; Liu XS; Young RA; Look AT
    Blood; 2006 Aug; 108(3):986-92. PubMed ID: 16621969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Helix-loop-helix (E2-5, HEB, TAL1 and Id1) protein interaction with the TCRalphadelta enhancers.
    Bernard M; Delabesse E; Smit L; Millien C; Kirsch IR; Strominger JL; Macintyre EA
    Int Immunol; 1998 Oct; 10(10):1539-49. PubMed ID: 9796921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant activation of the GIMAP enhancer by oncogenic transcription factors in T-cell acute lymphoblastic leukemia.
    Liau WS; Tan SH; Ngoc PCT; Wang CQ; Tergaonkar V; Feng H; Gong Z; Osato M; Look AT; Sanda T
    Leukemia; 2017 Aug; 31(8):1798-1807. PubMed ID: 28028313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S1P-S1PR3-RAS promotes the progression of S1PR3
    Zhu D; Jiang T; Ma D; Zhang H; Zhang J; Lv W; Gong M; Wang H; Liu Z; Su H; Zeng L; Liu S; Tang S; Yang B; Tshavuka FI; Fu G; Liu Z; Peng D; Liu H; Yan Z; Cao Z; Zhao H; He TC; Yu J; Shu Y; Zou L
    Leukemia; 2023 Oct; 37(10):1982-1993. PubMed ID: 37591940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SIX6 is a TAL1-regulated transcription factor in T-ALL and associated with inferior outcome.
    Laukkanen S; Oksa L; Nikkilä A; Lahnalampi M; Parikka M; Seki M; Takita J; Degerman S; de Bock CE; Heinäniemi M; Lohi O
    Leuk Lymphoma; 2020 Dec; 61(13):3089-3100. PubMed ID: 32835548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alteration of CTCF-associated chromatin neighborhood inhibits TAL1-driven oncogenic transcription program and leukemogenesis.
    Li Y; Liao Z; Luo H; Benyoucef A; Kang Y; Lai Q; Dovat S; Miller B; Chepelev I; Li Y; Zhao K; Brand M; Huang S
    Nucleic Acids Res; 2020 Apr; 48(6):3119-3133. PubMed ID: 32086528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-7 Functions as a Tumor Suppressor by Targeting the Oncogenes TAL1 in T-Cell Acute Lymphoblastic Leukemia.
    Sun H; Zhang Z; Luo W; Liu J; Lou Y; Xia S
    Technol Cancer Res Treat; 2020; 19():1533033820934130. PubMed ID: 32633635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptional activity of TAL1 in T cell acute lymphoblastic leukemia (T-ALL) requires RBTN1 or -2 and induces TALLA1, a highly specific tumor marker of T-ALL.
    Ono Y; Fukuhara N; Yoshie O
    J Biol Chem; 1997 Feb; 272(7):4576-81. PubMed ID: 9020185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-193b-3p acts as a tumor suppressor by targeting the MYB oncogene in T-cell acute lymphoblastic leukemia.
    Mets E; Van der Meulen J; Van Peer G; Boice M; Mestdagh P; Van de Walle I; Lammens T; Goossens S; De Moerloose B; Benoit Y; Van Roy N; Clappier E; Poppe B; Vandesompele J; Wendel HG; Taghon T; Rondou P; Soulier J; Van Vlierberghe P; Speleman F
    Leukemia; 2015 Apr; 29(4):798-806. PubMed ID: 25231743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.